COVID-19 Virus Infection

• EMA approval · 2026-08-12
  EMA Authorised: Comirnaty (single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — BioNTech Manufacturing GmbH

  EC/EMA authorised Comirnaty (BioNTech) for COVID-19, an mRNA vaccine encoding SARS-CoV-2 spike protein.

• EMA approval · 2026-08-07
  EMA Authorised: Nuvaxovid (SARS CoV-2 (Original) recombinant spike protein;SARS-CoV-2 (Omicron XBB.1.5) recombinant spike protein) — Sanofi Winthrop Industrie

  EMA has authorised Nuvaxovid (SARS-CoV-2 original and Omicron XBB.1.5 recombinant spike proteins) for COVID-19 virus infection.

• EMA approval · 2026-07-16
  EMA Authorised: Bimervax (SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion dimer produced by recombinant DNA technology) — Hipra Human Health S.L.

  EMA authorised Bimervax, a SARS-CoV-2 RBD-fusion dimer vaccine, for COVID-19 infection.

• EMA approval · 2026-04-29
  EMA Authorised: Comirnaty (single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2) — BioNTech Manufacturing GmbH

  Comirnaty (BioNTech) has been authorised by the EMA for use in COVID-19, with the active substance being mRNA encoding the SARS-CoV-2 spike …

• EMA withdrawal · 2025-09-01
  EMA Withdrawn: Jcovden (previously COVID-19 Vaccine Janssen) (adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)) — Janssen-Cilag International NV

  The EMA has withdrawn the European marketing authorization for Jcovden (COVID-19 vaccine Janssen), an Ad26.COV2-S vaccine, effective as of 2…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• EMA withdrawal · 2023-12-01
  EMA Withdrawn: COVID-19 Vaccine (inactivated, adjuvanted) Valneva (COVID-19 vaccine (inactivated, adjuvanted, adsorbed)) — Valneva Austria GmbH

  The EMA withdrew the COVID-19 vaccine (inactivated, adjuvanted, adsorbed) from Valneva Austria GmbH.

• CLINICAL_TRIALS trial_result · 2022-07-07
  Clinical Trial Update: Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus [Phase 2]

  Phase 2 clinical trial assessing the effect of a food supplement in people infected with COVID-19 has been completed.

• CLINICAL_TRIALS withdrawal · 2021-11-24
  Clinical Trial Update: High-Dose Corticosteroid or Tocilizumab for Clinical Worsening of COVID-19 [Phase 4]

  Phase 4 trial investigating high-dose corticosteroids or tocilizumab for clinical worsening in COVID-19 has been withdrawn.